Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Zhebei Granule is a traditional Chinese medicine herbal formulation used as an adjunct to chemotherapy in the treatment of refractory acute leukemia. Clinical studies have shown that when combined with standard chemotherapy regimens, Compound Zhebei Granule can significantly improve clinical remission rates and reduce the proportion of leukemia stem cells (CD34(+) CD123(+), CD33(+) CD123(+)) in patients with acute myeloid leukemia. The mechanism appears to involve modulation of leukemic cell surface markers and possibly enhancement of chemosensitivity, though precise molecular targets are not fully elucidated. It is administered orally as a granulated preparation during chemotherapy cycles[1][5][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound zhebei granule.